PROBLEM TO BE SOLVED: To provide a composition comprising rotigotine or a pharmaceutically acceptable salt thereof used for treating Parkinson's disease, having a greatly reduced burst release effect.SOLUTION: The invention relates to a composition containing about 20-40% of rotigotine or a pharmaceutically acceptable salt thereof; about 57.5-72.5% of at least one poly (lactide-co-glycolide) having a molecular weight of about 5000-100000 Da; and about 2.5-7.5% of at least one fatty acid having 8-24 carbon atoms. The pharmaceutically acceptable salt is a salt formed with an inorganic acid comprising hydrochloric acid, sulphuric acid, phosphoric acid, and nitric acid, or an organic acid comprising citric acid, fumaric acid, maleic acid, acetic acid, benzoic acid, lactic acid, methanesulfonic acid, or toluenesulfonic acid, or an acidic amino acid such as glutamic acid or aspartic acid.SELECTED DRAWING: None【課題】パーキンソン病を治療するロチゴチン又はその薬学的に許容可能な塩を含む大幅に減少したバースト放出効果を有する組成物の提供。【解決手段】ロチゴチン又はその薬学的に許容可能な塩を約20%~40%と、分子量が約5000~100000Daである少なくとも1つのポリ(ラクチド-co-グリコリド)が約57.5~72.5%と、炭素原子数8~24の少なくとも1つの脂肪酸が約2.5~7.5%と、を含有する組成物。前記薬学的に許容可能な塩が塩酸、硫酸、燐酸或いは硝酸かなる無機酸又はクエン酸、フマル酸、マレイン酸、酢酸、安息香酸、乳酸、メタスルホン酸或いはトルエンスルホン酸若しくはグルタミン酸或いはアスパラギン酸の酸性アミノ酸等の有機酸を形成される塩である組成物。【選択図】なし